ALK and non-small cell lung carcinoma: Other clinical trials are evaluating the benefit of ensartinib, a second-generation ALK-TKI, in resected NSCLC pts with a scheme of 225 mg die, both as an alternative to standard adjuvant CT (NCT05341583, phase III trial with ensartinib for 2 years versus placebo; NCT05186506, phase II trial with ensartinib for 2 years versus adjuvant CT) or after it (NCT05241028, phase II trial with ensartinib for 3 years).